Latest Novozymes Unspn ADR (NVZMY) Headlines
Post# of 5
Posted On: 03/10/2014 8:39:38 PM
Latest Novozymes Unspn ADR (NVZMY) Headlines
Rockwood Repays Sachtleben Debts - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 27, 1:20PM CDT
Rockwood has repaid all outstanding borrowings under the secured facility of its fully-owned unit Sachtleben.
American Vanguard Tops in 4Q - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 07, 8:40AM CST
American Vanguard's fourth-quarter revenues and earnings were ahead of the Zacks Consensus Estimates.
Chemtura Misses Squarely - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 01, 8:50AM CST
Chemtura's fourth-quarter revenues and earnings missed the Zacks Consensus Estimates.
Rockwood Hikes Dividend - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 26, 6:55PM CST
Rockwood has increased its quarterly dividend by 15%.
Valspar Reaffirmed at Neutral - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 20, 3:40PM CST
We have retained our Neutral recommendation on paint and coatings maker Valspar Corporation.
Rockwood to Control Sachtleben - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 19, 7:10PM CST
Rockwood is acquiring full ownership of Sachtleben.
Sigma-Aldrich Hikes Dividend - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 19, 5:56PM CST
Sigma-Aldrich has increased its quarterly dividend by 7.5%.
Sigma-Aldrich Inks Deal with Olink - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 14, 6:20PM CST
Sigma-Aldrich has partnered with Olink Bioscience to distribute Duolink In Situ products worldwide.
ImmunoGen Progresses with IMGN901 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 14, 5:45PM CST
ImmunoGen Inc announced that it has finished enrolling patients for the initial stage of the two-stage NORTH phase II trial
Sigma-Aldrich Retained at Neutral - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 13, 3:00PM CST
We have maintained our Neutral recommendation on Sigma-Aldrich.
Rockwood Repays Sachtleben Debts - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 27, 1:20PM CDT
Rockwood has repaid all outstanding borrowings under the secured facility of its fully-owned unit Sachtleben.
American Vanguard Tops in 4Q - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 07, 8:40AM CST
American Vanguard's fourth-quarter revenues and earnings were ahead of the Zacks Consensus Estimates.
Chemtura Misses Squarely - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 01, 8:50AM CST
Chemtura's fourth-quarter revenues and earnings missed the Zacks Consensus Estimates.
Rockwood Hikes Dividend - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 26, 6:55PM CST
Rockwood has increased its quarterly dividend by 15%.
Valspar Reaffirmed at Neutral - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 20, 3:40PM CST
We have retained our Neutral recommendation on paint and coatings maker Valspar Corporation.
Rockwood to Control Sachtleben - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 19, 7:10PM CST
Rockwood is acquiring full ownership of Sachtleben.
Sigma-Aldrich Hikes Dividend - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 19, 5:56PM CST
Sigma-Aldrich has increased its quarterly dividend by 7.5%.
Sigma-Aldrich Inks Deal with Olink - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 14, 6:20PM CST
Sigma-Aldrich has partnered with Olink Bioscience to distribute Duolink In Situ products worldwide.
ImmunoGen Progresses with IMGN901 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 14, 5:45PM CST
ImmunoGen Inc announced that it has finished enrolling patients for the initial stage of the two-stage NORTH phase II trial
Sigma-Aldrich Retained at Neutral - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 13, 3:00PM CST
We have maintained our Neutral recommendation on Sigma-Aldrich.
(0)
(0)